奋乃静可减轻 2 型过敏性皮炎小鼠模型的促炎反应。
Perphenazine Attenuates the Pro-Inflammatory Responses in Mouse Models of Th2-Type Allergic Dermatitis.
机构信息
Korea Institute of Dermatological Science, GeneCellPharm Corporation, 375 Munjeong 2(i)-dong, Songpa-gu, Seoul 05836, Korea.
Research Institute for Molecular-Targeted Drugs, Department of Cosmetics Engineering, Konkuk University, Seoul 05029, Korea.
出版信息
Int J Mol Sci. 2020 May 3;21(9):3241. doi: 10.3390/ijms21093241.
Developing dermatitis therapeutics has been faced with challenges including adverse effects of topical steroid and high cost of new developing drugs. Here, we found the expression levels of dopamine receptor D2 is higher in skin biopsies of dermatitis patients and an oxazolone-induced animal model of dermatitis. We used perphenazine, an FDA-approved dopamine receptor antagonist to determine the therapeutic effect. Two different animal models including 12-o-tetradecanoylphorbol-13-acetate (TPA) and oxazolone (OXA)-induced dermatitis were employed. TPA and OXA-mediated ear swelling was attenuated by perphenazine. Moreover, perphenazine inhibited infiltrated mast cells into lesion area. We found levels of serum IgE, histamine and cytokines are decreased in mice cotreated with perphenazine and OXA compared to OXA-treated mice. Overall, this is a first study showing that the FDA-approved, anti-psychotic drug, perphenazine, alleviates animal models of dermatitis.
开发治疗皮炎的药物一直面临着挑战，包括局部类固醇的副作用和新药开发的高成本。在这里，我们发现皮炎患者的皮肤活检样本和一种氧化唑诱导的动物皮炎模型中多巴胺受体 D2 的表达水平更高。我们使用了已获 FDA 批准的多巴胺受体拮抗剂奋乃静来确定其治疗效果。我们使用了两种不同的动物模型，包括 12-O-十四烷酰佛波醇-13-乙酸酯（TPA）和氧化唑（OXA）诱导的皮炎。奋乃静可减轻 TPA 和 OXA 介导的耳部肿胀。此外，奋乃静抑制了浸润到病变区域的肥大细胞。我们发现与 OXA 处理的小鼠相比，同时用奋乃静和 OXA 处理的小鼠血清 IgE、组胺和细胞因子水平降低。总的来说，这是第一项表明 FDA 批准的抗精神病药物奋乃静可缓解皮炎动物模型的研究。
Zotero 插件